Linked Life Data

17419956

Source:http://linkedlifedata.com/resource/pubmed/id/17419956

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
5
pubmed:dateCreated
2007-4-10
pubmed:abstractText
Effectively evaluating disease-modifying effects in clinical trials has posed a problem for clinical trialists and drug development. One method that has been proposed to evaluate disease-modifying effects has been the re-randomization of active group participants to discontinue the intervention after a period sufficient to produce therapeutic effects. We aimed to determine if this design would permit inferences regarding disease modification in a trial evaluating Pegaptanib sodium, an intra-ocular injection, for the treatment of age-related macular degeneration.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
May
pubmed:issn
0895-4356
pubmed:author
pubmed:issnType
Print
pubmed:volume
60
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
456-60
pubmed:meshHeading
pubmed:year
2007
pubmed:articleTitle
A randomized trial of Pegaptanib sodium for age-related macular degeneration used an innovative design to explore disease-modifying effects.
pubmed:affiliation
Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, Ontario, Canada. millsej@mcmaster.ca
pubmed:publicationType
Journal Article, Randomized Controlled Trial, Multicenter Study